OGN

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 13

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,765

Underlying: Common Stock · 23,765 shares

Expires 2029-05-02

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F10 · derivative.exercise_date: 15,841 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 12

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,810

Underlying: Common Stock · 30,810 shares

Expires 2028-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 11

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,039

Underlying: Common Stock · 45,039 shares

Expires 2027-05-04

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 10

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,177

Underlying: Common Stock · 57,177 shares

Expires 2026-05-09

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 9

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,132

Underlying: Common Stock · 52,132 shares

Expires 2025-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 8

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,323

Underlying: Common Stock · 46,323 shares

Expires 2024-05-01

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 7

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,319

Underlying: Common Stock · 14,319 shares

Expires 2023-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 6

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,266

Underlying: Common Stock · 6,266 shares

Expires 2022-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 5

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,814

Underlying: Common Stock · 5,814 shares

Expires 2021-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 4

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,802

Underlying: Common Stock · 10,802 shares

Expires 2024-05-04

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 3

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,980

Underlying: Common Stock · 2,980 shares

Expires 2023-05-01

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 2

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,807

Underlying: Common Stock · 2,807 shares

Expires 2022-05-03

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 15

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 515,471

Underlying: Common Stock · 515,471 shares

Expires 2031-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 14

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,578

Underlying: Common Stock · 63,578 shares

Expires 2030-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F11 · derivative.exercise_date: 21,191 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 13

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,412

Underlying: Common Stock · 59,412 shares

Expires 2029-05-02

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F10 · derivative.exercise_date: 39,608 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 12

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,028

Underlying: Common Stock · 77,028 shares

Expires 2028-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 11

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,063

Underlying: Common Stock · 72,063 shares

Expires 2027-05-04

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 10

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,120

Underlying: Common Stock · 38,120 shares

Expires 2026-05-09

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 9

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,821

Underlying: Common Stock · 60,821 shares

Expires 2025-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 8

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,021

Underlying: Common Stock · 27,021 shares

Expires 2024-05-01

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 7

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,121

Underlying: Common Stock · 88,121 shares

Expires 2023-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 6

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,393

Underlying: Common Stock · 11,393 shares

Expires 2022-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 5

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,528

Underlying: Common Stock · 14,528 shares

Expires 2021-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 4

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,477

Underlying: Common Stock · 66,477 shares

Expires 2024-05-04

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 3

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,420

Underlying: Common Stock · 5,420 shares

Expires 2023-05-01

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022190 · doc4.xml · derivative · entry 2

Ali Kevin · CIK 0001859698 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,631

Underlying: Common Stock · 2,631 shares

Expires 2022-05-03

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 11

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,325

Underlying: Common Stock · 48,325 shares

Expires 2031-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 10

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,073

Underlying: Common Stock · 19,073 shares

Expires 2030-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F11 · derivative.exercise_date: 6,356 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 9

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,257

Underlying: Common Stock · 14,257 shares

Expires 2029-05-02

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F10 · derivative.exercise_date: 9,505 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 8

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,325

Underlying: Common Stock · 12,325 shares

Expires 2028-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 7

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,261

Underlying: Common Stock · 8,261 shares

Expires 2023-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 6

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,418

Underlying: Common Stock · 3,418 shares

Expires 2022-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 5

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,486

Underlying: Common Stock · 3,486 shares

Expires 2021-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 4

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,232

Underlying: Common Stock · 6,232 shares

Expires 2024-05-04

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 3

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,627

Underlying: Common Stock · 1,627 shares

Expires 2023-05-01

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022186 · doc4.xml · derivative · entry 2

Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 631

Underlying: Common Stock · 631 shares

Expires 2022-05-03

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 14

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,104

Underlying: Common Stock · 45,104 shares

Expires 2031-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 13

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,887

Underlying: Common Stock · 22,887 shares

Expires 2030-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F11 · derivative.exercise_date: 7,627 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 12

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,446

Underlying: Common Stock · 15,446 shares

Expires 2029-05-02

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F10 · derivative.exercise_date: 10,296 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 11

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,022

Underlying: Common Stock · 16,022 shares

Expires 2028-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 10

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,835

Underlying: Common Stock · 21,835 shares

Expires 2026-05-09

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 9

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,132

Underlying: Common Stock · 52,132 shares

Expires 2025-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 8

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,170

Underlying: Common Stock · 23,170 shares

Expires 2024-05-01

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 7

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,710

Underlying: Common Stock · 7,710 shares

Expires 2023-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 6

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,102

Underlying: Common Stock · 4,102 shares

Expires 2022-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 5

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,776

Underlying: Common Stock · 3,776 shares

Expires 2021-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 4

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,818

Underlying: Common Stock · 5,818 shares

Expires 2024-05-04

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 3

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,951

Underlying: Common Stock · 1,951 shares

Expires 2023-05-01

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022185 · doc4.xml · derivative · entry 2

Ritter Geralyn S · CIK 0001859678 · Hd of Ext. Affairs and ESG

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 684

Underlying: Common Stock · 684 shares

Expires 2022-05-03

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022060 · doc4.xml · nonDerivative · entry 1

Merck & Co., Inc. · CIK 0000310158 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. ("Merck") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the "Separation").

F2 · shares: In connection with the Separation, the 100 shares of common stock of Organon & Co. held by Merck were reclassified into 253,516,000 shares of common stock of Organon & Co.

F1 · price: Pursuant to the Separation and Distribution Agreement, dated as of June 2, 2021, Merck & Co., Inc. ("Merck") distributed to the holders of its common stock by means of a pro-rata distribution without consideration an aggregate of 253,516,000 shares of common stock of Organon & Co. (the "Separation").